1. Home
  2. VTAK vs ARTL Comparison

VTAK vs ARTL Comparison

Compare VTAK & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VTAK
  • ARTL
  • Stock Information
  • Founded
  • VTAK 2002
  • ARTL 2011
  • Country
  • VTAK United States
  • ARTL United States
  • Employees
  • VTAK N/A
  • ARTL N/A
  • Industry
  • VTAK Medical/Dental Instruments
  • ARTL Biotechnology: Pharmaceutical Preparations
  • Sector
  • VTAK Health Care
  • ARTL Health Care
  • Exchange
  • VTAK Nasdaq
  • ARTL Nasdaq
  • Market Cap
  • VTAK 3.1M
  • ARTL 3.1M
  • IPO Year
  • VTAK 2018
  • ARTL N/A
  • Fundamental
  • Price
  • VTAK $0.30
  • ARTL $6.03
  • Analyst Decision
  • VTAK
  • ARTL Buy
  • Analyst Count
  • VTAK 0
  • ARTL 2
  • Target Price
  • VTAK N/A
  • ARTL $30.00
  • AVG Volume (30 Days)
  • VTAK 41.4M
  • ARTL 13.2K
  • Earning Date
  • VTAK 08-13-2025
  • ARTL 08-12-2025
  • Dividend Yield
  • VTAK N/A
  • ARTL N/A
  • EPS Growth
  • VTAK N/A
  • ARTL N/A
  • EPS
  • VTAK N/A
  • ARTL N/A
  • Revenue
  • VTAK $481,000.00
  • ARTL N/A
  • Revenue This Year
  • VTAK $822.86
  • ARTL N/A
  • Revenue Next Year
  • VTAK $168.42
  • ARTL N/A
  • P/E Ratio
  • VTAK N/A
  • ARTL N/A
  • Revenue Growth
  • VTAK 9.57
  • ARTL N/A
  • 52 Week Low
  • VTAK $0.16
  • ARTL $4.92
  • 52 Week High
  • VTAK $8.40
  • ARTL $9.30
  • Technical
  • Relative Strength Index (RSI)
  • VTAK 50.43
  • ARTL 43.05
  • Support Level
  • VTAK $0.25
  • ARTL $6.20
  • Resistance Level
  • VTAK $0.38
  • ARTL $7.35
  • Average True Range (ATR)
  • VTAK 0.07
  • ARTL 0.45
  • MACD
  • VTAK 0.01
  • ARTL -0.09
  • Stochastic Oscillator
  • VTAK 18.46
  • ARTL 0.00

About VTAK Catheter Precision Inc.

Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System), which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Share on Social Networks: